-
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and…
-
AION UT Posts 60% Month-on-Month Growth in May, Becoming the Fastest-Growing Chinese EV Hatchback
GUANGZHOU, China, June 18, 2026 /PRNewswire/ — The global momentum of the AION UT continued to build in May 2026, with monthly sales reaching 3,331 units – a 60% increase month-on-month – making it the fastest-growing Chinese-brand electric hatchback in its segment. Since its global debut in 2025, the AION UT has rapidly expanded across Southeast…
-
Morepen Labs Q4 Net Profit Rises 69 percent; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10 percent for FY 2025-26
Gurugram, Haryana, India Morepen Laboratories Limited reported strong Q4 FY26 performance with net profit rising 69% YoY to Rs. 20 crore and gross revenue increasing 22% YoY to Rs. 472 crore. Revenue growth during the quarter was supported by export momentum and expansion in the Medical Devices business, while operational momentum strengthened toward the latter…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.